Jiamei Chen

Jiamei Chen

Auto-generated profile, based on publicly available information

Jiamei Chen

Institute of Liver Diseases, Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2020 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
ZXZhun Xiao
Zhun Xiao
WLWei Liu
Wei Liu
YMYong-Ping Mu
Yong-Ping Mu
HZHua Zhang
Hua Zhang
XWXiao-Ning Wang
Xiao-Ning Wang
PLPing Liu
Ping Liu
Salvianolic acid B (Sal B) is one of the main active ingredients of Salvia miltiorrhiza, with strong antioxidant effects. Recent findings have shown that Sal B has anti-inflammatory, anti-apoptotic, anti-fibrotic effects and can promote stem cell proliferation and differentiation, and has a beneficial effect on cardiovascular and cerebrovascular diseases, aging, and liver fibrosis. Reactive oxygen species (ROS) include oxygen free radicals and oxygen-containing non-free radicals. ROS can regulate cell proliferation, survival, death and differentiation to regulate inflammation, and immunity, while Sal B can scavenge oxygen free radicals by providing hydrogen atoms and reduce the production of oxygen free radicals and oxygen-containing non-radicals by regulating the expression of antioxidant enzymes. The many pharmacological effects of Sal B may be closely related to its elimination and inhibition of ROS generation, and Nuclear factor E2-related factor 2/Kelch-like ECH-related protein 1 may be the core link in its regulation of the expression of antioxidant enzyme to exert its antioxidant effect. What is confusing and interesting is that Sal B exhibits the opposite mechanisms in tumors. To clarify the specific target of Sal B and the correlation between its regulation of oxidative stress and energy metabolism homeostasis will help to further understand its role in different pathological conditions, and provide a scientific basis for its further clinical application and new drug development. Although Sal B has broad prospects in clinical application due to its extensive pharmacological effects, the low bioavailability is a serious obstacle to further improving its efficacy in vivo and promoting clinical application. Therefore, how to improve the availability of Sal B in vivo requires the joint efforts of many interdisciplinary subjects.

4 January 2024 in Redox Biology
Verified
Journal Article
Open access
YFYadong Fu
Yadong Fu
XZXiaoxi Zhou
Xiaoxi Zhou
LWLin Wang
Lin Wang
WFWeiguo Fan
Weiguo Fan
SGSiqi Gao
Siqi Gao
PLPing Liu
Ping Liu
Hepatocyte ferroptosis promotes the pathogenesis and progression of liver fibrosis. Salvianolic acid B (Sal B) exerts antifibrotic effects. However, the pharmacological mechanism and target has not yet been fully elucidated. In this study, liver fibrosis was induced by CCl4 in wild-type mice and hepatocyte-specific extracellular matrix protein 1 (Ecm1)-deficient mice, which were separately treated with Sal B, ferrostatin-1, sorafenib or cilengitide. Erastin- or CCl4-induced hepatocyte ferroptosis models with or without Ecm1 gene knockdown were evaluated in vitro. Subsequently, the interaction between Ecm1 and xCT and the binding kinetics of Sal B and Ecm1 were determined. We found that Sal B significantly attenuated liver fibrosis in CCl4-induced mice. Ecm1 deletion in hepatocytes abolished the antifibrotic effect of Sal B. Mechanistically, Sal B protected against hepatocyte ferroptosis by upregulating Ecm1. Further research revealed that Ecm1 as a direct target for treating liver fibrosis with Sal B. Interestingly, Ecm1 interacted with xCT to regulate hepatocyte ferroptosis. Hepatocyte ferroptosis in vitro was significantly attenuated by Sal B treatment, which was abrogated after knockdown of Ecm1 in LO2 cells. Therefore, Sal B alleviates liver fibrosis in mice by targeting up-regulation of Ecm1 and inhibiting hepatocyte ferroptosis. The interaction between Ecm1 and xCT regulates hepatocyte ferroptosis.

1 July 2023 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
LZLinzhang Zhang
Linzhang Zhang
JSJiewen Shi
Jiewen Shi
QSQin Shen
Qin Shen
YFYadong Fu
Yadong Fu
SQShenglan Qi
Shenglan Qi
WLWei Liu
Wei Liu

3 June 2022 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
XZXiaoxi Zhou
Xiaoxi Zhou
YFYadong Fu
Yadong Fu
WLWei Liu
Wei Liu
YMYongping Mu
Yongping Mu
HZHua Zhang
Hua Zhang
PLPing Liu
Ping Liu
Ferroptosis, an iron-dependent non-apoptotic cell death characterized by lipid peroxidation, is a cell death pathway discovered in recent years. Ferroptosis plays an important role in tumors, ischemia-reperfusion injury, neurological diseases, blood diseases, etc. Recent studies have shown the importance of ferroptosis in chronic liver disease. This article summarizes the pathological mechanisms of ferroptosis involved in System Xc−, iron metabolism, lipid metabolism, and some GPX4-independent pathways, and the latest research on ferroptosis in chronic liver diseases such as alcoholic liver disease, non-alcoholic fatty liver disease, liver fibrosis, hepatocellular carcinoma. In addition, the current bottleneck issues that restrict the research on ferroptosis are proposed to provide ideas and strategies for exploring new therapeutic targets for chronic liver diseases.

1 January 2024 in Theranostics
Verified
Journal Article
Open access
PDF file
YHYonghong Hu
Yonghong Hu
XBXinyu Bao
Xinyu Bao
ZZZheng Zhang
Zheng Zhang
LCLong Chen
Long Chen
YLYue Liang
Yue Liang
JCJiamei Chen
Jiamei Chen
Background: It is poorly understood what cellular types participate in ductular reaction (DR) and whether DR facilitates recovery from injury or accelerates hepatic fibrosis. The aim of this study is to gain insights into the role of hepatic progenitor cell (HPC)-originated DR during fibrotic progression.

1 January 2017 in The American Journal of Chinese Medicine
Verified
Journal Article
Closed access
XZXiao Zhang
Xiao Zhang
YXYing Xu
Ying Xu
JCJia-Mei Chen
Jia-Mei Chen
CLCheng Liu
Cheng Liu
GDGuang-Li Du
Guang-Li Du
PLPing Liu
Ping Liu